News Update DE - APTA Therapeutics

APTA Therapeutics welcomes Dr. Daniel Bock as Chief Scientific Officer / Chief Operational Officer

2. September 2025

APTA Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for diseases associated with regulatory autoantibodies, strengthens its management team.

Interview with CEO Dr. Oliver von Stein in „The Sick Times“

22. Juli 2025

Click here for the article:

https://thesicktimes.org/2025/07/22/berlin-cures-failed-long-covid-clinical-trial-yields-lessons-on-study-design/

APTA Therapeutics acquires all assets from Berlin Cures

1. Juli 2025

The newly founded APTA Therapeutics has acquired assets from Berlin Cures and intends to continue clinical development of rovunaptabin, formally BC 007.

News Room

News Room

APTA Therapeutics welcomes Dr. Daniel Bock as Chief Scientific Officer / Chief Operational Officer

Interview with CEO Dr. Oliver von Stein in „The Sick Times“

APTA Therapeutics acquires all assets from Berlin Cures